Minimal Residual Disease Monitoring: Advances, Clinical Relevance, and Guideline-Based Perspectives

Abstract

Minimal residual disease (MRD) monitoring has emerged as a pivotal tool in the management of hematologic malignancies, enabling the detection of subclinical disease persistence and informing therapeutic decisions. This review synthesizes current evidence, elucidates the scientific basis of MRD assessment, highlights epidemiological trends, and discusses practical implications in clinical practice. We also address recent technological advances, guideline recommendations, and future directions in MRD monitoring, aiming to provide a comprehensive resource for clinicians and researchers engaged in the care of patients with hematologic cancers.

Introduction

MRD refers to the small number of malignant cells that remain in a patient during or after treatment, undetectable by conventional morphologic methods but identifiable by sensitive molecular, cytogenetic, or flow cytometric techniques. The accurate assessment of MRD has revolutionized the prognostic stratification, therapeutic tailoring, and surveillance strategies in hematologic malignancies, particularly acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL). MRD monitoring is increasingly incorporated into clinical trials and routine care, serving as a surrogate endpoint for therapeutic efficacy and relapse risk.

Epidemiology / Disease Burden

The global burden of hematologic malignancies, including leukemias, lymphomas, and multiple myeloma, is substantial, with millions affected worldwide. Despite advances in treatment, relapse remains a significant challenge, often attributed to residual disease below the threshold of conventional detection. Studies indicate that even in morphologic remission, up to 10-4 to 10-6 malignant cells can persist, underscoring the necessity for highly sensitive MRD monitoring. Epidemiological analyses reveal that MRD positivity post-therapy correlates strongly with relapse rates and is a major determinant of long-term survival across various hematologic cancers.

Pathophysiology

MRD arises from the survival of a subpopulation of malignant cells that evade eradication by standard therapies. These cells may possess intrinsic resistance mechanisms, reside in protective niches within the bone marrow microenvironment, or express altered antigenic profiles. Clonal evolution under therapeutic pressure can lead to genetic and epigenetic diversification, further complicating eradication. Understanding the biological underpinnings of MRD is crucial for developing targeted interventions and improving patient outcomes.

Risk Factors

Several risk factors influence MRD persistence and detection. High initial disease burden, adverse cytogenetic or molecular features (such as t(9;22) in ALL or FLT3-ITD in AML), suboptimal response to induction therapy, and poor-risk immunophenotypic profiles are associated with increased MRD positivity. Patient-specific factors, including age, comorbidities, and immune competence, also modulate MRD kinetics and prognostic significance. Recognizing these risk factors facilitates risk-adapted monitoring and treatment strategies.

Clinical Features

By definition, MRD is a subclinical state, and patients with MRD positivity are typically asymptomatic in the absence of overt relapse. However, MRD assessment provides critical prognostic information beyond clinical and morphological parameters, enabling identification of patients at high risk for relapse even in the absence of clinical progression. Persistent or rising MRD levels may precede hematologic relapse, offering a window for preemptive therapeutic intervention.

Diagnosis

MRD detection relies on highly sensitive modalities, including multiparameter flow cytometry (MFC), real-time quantitative polymerase chain reaction (qPCR), and next-generation sequencing (NGS). Each technique offers distinct advantages: MFC is rapid and broadly applicable, qPCR provides high sensitivity for specific genetic targets (e.g., BCR-ABL1, NPM1), while NGS enables ultra-deep profiling of clonal rearrangements with sensitivities up to 10-6. Standardization of MRD assays and harmonization of reporting criteria have been prioritized by international working groups to ensure reproducibility and clinical utility.

Treatment & Management

MRD status informs critical aspects of treatment, including risk stratification, duration and intensity of therapy, and eligibility for allogeneic hematopoietic stem cell transplantation (HSCT). In ALL, MRD-guided therapy has been shown to improve survival by tailoring treatment intensity and reducing overtreatment-related toxicity. In AML and CLL, MRD monitoring is increasingly utilized to identify candidates for consolidation therapy or novel agents. Persistent MRD may prompt escalation of therapy, enrollment in clinical trials, or preemptive interventions aimed at eradicating residual disease.

Recent Advances / Emerging Therapies

Technological innovations have propelled the sensitivity and applicability of MRD monitoring. Digital PCR and ultra-deep NGS offer unprecedented detection limits, enabling the identification of ultra-rare malignant clones. Novel immunotherapeutic agents, such as bispecific T-cell engagers and CAR-T cell therapies, are evaluated for their capacity to achieve MRD negativity. Furthermore, liquid biopsy approaches utilizing cell-free DNA are under investigation for non-invasive MRD assessment. These advances promise to further refine prognostic models and therapeutic algorithms.

Guideline Recommendations

International guidelines, including those from the European LeukemiaNet (ELN), National Comprehensive Cancer Network (NCCN), and European Society for Blood and Marrow Transplantation (EBMT), endorse MRD monitoring as a standard of care in select hematologic malignancies. Recommendations emphasize assay standardization, regular MRD assessment at defined treatment intervals, and integration of MRD status into therapeutic decision-making. Guidelines also acknowledge the need for continued research to validate MRD-guided approaches in broader clinical contexts.

Conclusion

MRD monitoring represents a paradigm shift in hematologic oncology, enabling sensitive detection of residual disease, precise risk stratification, and individualized therapeutic strategies. Ongoing advances in assay technology and emerging targeted therapies are poised to enhance the prognostic and therapeutic value of MRD assessment. Future research should focus on expanding the clinical utility of MRD monitoring, refining intervention thresholds, and elucidating strategies to overcome residual disease, ultimately improving patient outcomes in hematologic malignancies.